Department of Surgery, Hirakata Hospital, Kansai Medical University, Hirakata, Osaka, Japan.
J Surg Oncol. 2010 Oct 1;102(5):462-8. doi: 10.1002/jso.21631.
Microvascular invasion (MVI) is difficult to detect before resection of hepatocellular carcinoma (HCC).
Clinicopathological and outcome data were retrospectively compared between 213 HCC patients with MVI and 221 patients without MVI who underwent hepatectomy.
MVI risk was selected as an independent prognostic indicator for both disease-free and overall survival in our 434 HCC patients. Univariate and multivariate analyses showed that an age under 65 years, a protein induced by vitamin K absence/antagonism II (PIVKA-II) level ≥200 mAU/ml, a preoperative tumor size ≥5.0 cm, and poorly differentiated carcinoma were independent predictors of MVI. When age, PIVKA-II level, and tumor size (data available before surgery) were scored as a combined index, the total score demonstrated a significant correlation with the extent of vascular invasion and with survival after hepatic resection.
An age under 65 years, increase of PIVKA-II, and larger tumor size were preoperative predictors of MVI in HCC patients undergoing potentially curative resection. Our combined score based on the age, serum PIVKA-II, and preoperative tumor size is a reliable predictor of MVI and survival in patients with HCC.
在肝癌(HCC)切除术前,微血管侵犯(MVI)难以检测。
回顾性比较了 213 例接受肝切除术的 HCC 伴 MVI 患者和 221 例无 MVI 患者的临床病理和预后数据。
MVI 风险是我们 434 例 HCC 患者无病和总生存的独立预后指标。单因素和多因素分析显示,年龄<65 岁、维生素 K 缺乏/拮抗剂 II 诱导蛋白(PIVKA-II)水平≥200 mAU/ml、术前肿瘤大小≥5.0 cm 和低分化癌是 MVI 的独立预测因素。当将年龄、PIVKA-II 水平和肿瘤大小(术前可用数据)评分作为综合指数时,总评分与血管侵犯程度和肝切除术后生存显著相关。
年龄<65 岁、PIVKA-II 升高和肿瘤较大是 HCC 患者行潜在根治性切除术后发生 MVI 的术前预测因素。我们基于年龄、血清 PIVKA-II 和术前肿瘤大小的综合评分是 HCC 患者 MVI 和生存的可靠预测指标。